Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

1.6%

1 terminated out of 63 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

21%

13 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results90% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (11)
Early P 1 (2)
P 2 (17)
P 3 (12)
P 4 (1)

Trial Status

Unknown24
Recruiting16
Completed9
Not Yet Recruiting8
Active Not Recruiting4
Terminated1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (63)

Showing 20 of 20 trials
NCT06986005Completed

The Effect of Neoadjuvant Chemotherapy on Physical Functions

NCT07413146Not ApplicableNot Yet Recruiting

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

NCT06220214Early Phase 1Recruiting

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

NCT05522985Phase 2Active Not Recruiting

Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07080944Not ApplicableRecruiting

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

NCT06998758Phase 3RecruitingPrimary

Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC

NCT07220512Recruiting

The Better, Harder, Faster, Stronger Study

NCT07159711Not Yet Recruiting

Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery

NCT07142863Phase 2Not Yet Recruiting

Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients

NCT03719833Completed

Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents

NCT07077018Not ApplicableNot Yet Recruiting

Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

NCT04922853Phase 3Active Not Recruiting

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

NCT07051083Recruiting

Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

NCT06975644Not ApplicableNot Yet Recruiting

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NCT06978322Recruiting

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

NCT03750669Phase 3Completed

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

NCT05092763Not ApplicableCompleted

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer

NCT06938906Active Not Recruiting

Multimodal Therapy Impact on Pancreatic Cancer Survival

NCT06497660Phase 4Recruiting

Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia

NCT06155305Recruiting

Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer

Scroll to load more

Research Network

Activity Timeline